Listed

Serina Therapeutics, Inc.

SERNYSECIK 1708599HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$0, Q2 FY2026
Operating income−$6.8m, Q2 FY2026
Net income−$6.4m, Q2 FY2026
Serina Therapeutics, Inc., income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Revenue$m0.0Revenue, Q3 FY2023, three months to 2023-09-30$29.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2024-11-12, accession 0001708599-24-000026.Report this figure3.1Revenue, Q4 FY2023, three months to 2023-12-31$3.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-24, accession 0001708599-25-000027. Derived: 12-month figure less the 9-month figure.Report this figure0.0Revenue, Q1 FY2024, three months to 2024-03-31$5.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-05-08, accession 0001708599-25-000053.Report this figure0.1Revenue, Q2 FY2024, three months to 2024-06-30$51.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-08-11, accession 0001708599-25-000089.Report this figure0.0Revenue, Q3 FY2024, three months to 2024-09-30$14.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-13, accession 0001708599-25-000133.Report this figure(0.0)Revenue, Q4 FY2024, three months to 2024-12-31−$14.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-25, accession 0001708599-26-000016. Derived: 12-month figure less the 9-month figure.Report this figure0.0Revenue, Q1 FY2025, three months to 2025-03-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-05-08, accession 0001708599-25-000053.Report this figure0.1Revenue, Q2 FY2025, three months to 2025-06-30$130.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-13, accession 0001708599-26-000047.Report this figure0.0Revenue, Q3 FY2025, three months to 2025-09-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-13, accession 0001708599-25-000133.Report this figure0.0Revenue, Q4 FY2025, three months to 2025-12-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-25, accession 0001708599-26-000016. Derived: 12-month figure less the 9-month figure.Report this figurenot reported0.0Revenue, Q2 FY2026, three months to 2026-06-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-13, accession 0001708599-26-000047.Report this figure
Cost of revenue$m0.0Cost of revenue, Q3 FY2023, three months to 2023-09-30$33.0k. XBRL concept us-gaap:CostOfRevenue. 10-Q filed 2023-11-14, accession 0001493152-23-041126.Report this figure0.0Cost of revenue, Q4 FY2023, three months to 2023-12-31$1.0k. XBRL concept us-gaap:CostOfRevenue. 10-K filed 2024-03-22, accession 0001493152-24-011022. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Gross profit$m0.0Gross profit, Q3 FY2023, three months to 2023-09-30$34.0k. XBRL concept us-gaap:GrossProfit. 10-Q filed 2023-11-14, accession 0001493152-23-041126.Report this figure0.1Gross profit, Q4 FY2023, three months to 2023-12-31$55.0k. XBRL concept us-gaap:GrossProfit. 10-K filed 2024-03-22, accession 0001493152-24-011022. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Research and development$m0.6Research and development, Q3 FY2023, three months to 2023-09-30$603.0k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-12, accession 0001708599-24-000026.Report this figure0.9Research and development, Q4 FY2023, three months to 2023-12-31$907.0k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2025-03-24, accession 0001708599-25-000027. Derived: 12-month figure less the 9-month figure.Report this figure1.1Research and development, Q1 FY2024, three months to 2024-03-31$1.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-08, accession 0001708599-25-000053.Report this figure1.6Research and development, Q2 FY2024, three months to 2024-06-30$1.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-11, accession 0001708599-25-000089.Report this figure2.4Research and development, Q3 FY2024, three months to 2024-09-30$2.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-13, accession 0001708599-25-000133.Report this figure2.4Research and development, Q4 FY2024, three months to 2024-12-31$2.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-25, accession 0001708599-26-000016. Derived: 12-month figure less the 9-month figure.Report this figure3.0Research and development, Q1 FY2025, three months to 2025-03-31$3.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-14, accession 0001708599-26-000035.Report this figure3.2Research and development, Q2 FY2025, three months to 2025-06-30$3.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-13, accession 0001708599-26-000047.Report this figure3.7Research and development, Q3 FY2025, three months to 2025-09-30$3.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-13, accession 0001708599-25-000133.Report this figure3.4Research and development, Q4 FY2025, three months to 2025-12-31$3.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-25, accession 0001708599-26-000016. Derived: 12-month figure less the 9-month figure.Report this figure3.2Research and development, Q1 FY2026, three months to 2026-03-31$3.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-14, accession 0001708599-26-000035.Report this figure3.8Research and development, Q2 FY2026, three months to 2026-06-30$3.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-13, accession 0001708599-26-000047.Report this figure
Operating income$m(1.5)Operating income, Q3 FY2023, three months to 2023-09-30−$1.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-12, accession 0001708599-24-000026.Report this figure0.2Operating income, Q4 FY2023, three months to 2023-12-31$241.0k. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-24, accession 0001708599-25-000027. Derived: 12-month figure less the 9-month figure.Report this figure(2.3)Operating income, Q1 FY2024, three months to 2024-03-31−$2.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-08, accession 0001708599-25-000053.Report this figure(3.9)Operating income, Q2 FY2024, three months to 2024-06-30−$3.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-11, accession 0001708599-25-000089.Report this figure(5.3)Operating income, Q3 FY2024, three months to 2024-09-30−$5.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-13, accession 0001708599-25-000133.Report this figure(5.5)Operating income, Q4 FY2024, three months to 2024-12-31−$5.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-25, accession 0001708599-26-000016. Derived: 12-month figure less the 9-month figure.Report this figure(5.9)Operating income, Q1 FY2025, three months to 2025-03-31−$5.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-08, accession 0001708599-25-000053.Report this figure(5.6)Operating income, Q2 FY2025, three months to 2025-06-30−$5.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-13, accession 0001708599-26-000047.Report this figure(6.4)Operating income, Q3 FY2025, three months to 2025-09-30−$6.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-13, accession 0001708599-25-000133.Report this figure(6.2)Operating income, Q4 FY2025, three months to 2025-12-31−$6.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-25, accession 0001708599-26-000016. Derived: 12-month figure less the 9-month figure.Report this figurenot reported(6.8)Operating income, Q2 FY2026, three months to 2026-06-30−$6.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-13, accession 0001708599-26-000047.Report this figure
Interest expense$m3.0Interest expense, Q3 FY2023, three months to 2023-09-30$3.0m. XBRL concept us-gaap:InterestExpense. 10-Q filed 2023-11-14, accession 0001493152-23-041126.Report this figure(0.0)Interest expense, Q4 FY2023, three months to 2023-12-31−$28.0k. XBRL concept us-gaap:InterestExpense. 10-K filed 2024-03-22, accession 0001493152-24-011022. Derived: 12-month figure less the 9-month figure.Report this figure0.1Interest expense, Q1 FY2024, three months to 2024-03-31$99.0k. XBRL concept us-gaap:InterestExpense. 10-Q filed 2024-05-14, accession 0001493152-24-019248.Report this figure0.3Interest expense, Q2 FY2024, three months to 2024-06-30$307.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-08-11, accession 0001708599-25-000089.Report this figure0.0Interest expense, Q3 FY2024, three months to 2024-09-30$16.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-11-13, accession 0001708599-25-000133.Report this figure0.0Interest expense, Q4 FY2024, three months to 2024-12-31$17.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-K filed 2026-03-25, accession 0001708599-26-000016. Derived: 12-month figure less the 9-month figure.Report this figure0.0Interest expense, Q1 FY2025, three months to 2025-03-31$0. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-05-14, accession 0001708599-26-000035.Report this figure0.0Interest expense, Q2 FY2025, three months to 2025-06-30$9.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-08-13, accession 0001708599-26-000047.Report this figure0.0Interest expense, Q3 FY2025, three months to 2025-09-30$6.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-11-13, accession 0001708599-25-000133.Report this figure0.2Interest expense, Q4 FY2025, three months to 2025-12-31$198.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-K filed 2026-03-25, accession 0001708599-26-000016. Derived: 12-month figure less the 9-month figure.Report this figure0.2Interest expense, Q1 FY2026, three months to 2026-03-31$189.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-05-14, accession 0001708599-26-000035.Report this figure0.2Interest expense, Q2 FY2026, three months to 2026-06-30$203.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-08-13, accession 0001708599-26-000047.Report this figure
Income tax$m0.0Income tax, Q3 FY2023, three months to 2023-09-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2023-11-14, accession 0001493152-23-041126.Report this figure0.0Income tax, Q4 FY2023, three months to 2023-12-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2025-03-24, accession 0001708599-25-000027. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reportednot reportednot reported0.0Income tax, Q1 FY2025, three months to 2025-03-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-05-14, accession 0001708599-26-000035.Report this figurenot reportednot reportednot reported0.0Income tax, Q1 FY2026, three months to 2026-03-31$7.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-05-14, accession 0001708599-26-000035.Report this figurenot reported
Net income$m1.8Net income, Q3 FY2023, three months to 2023-09-30$1.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-12, accession 0001708599-24-000026.Report this figure1.1Net income, Q4 FY2023, three months to 2023-12-31$1.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-24, accession 0001708599-25-000027. Derived: 12-month figure less the 9-month figure.Report this figure(15.0)Net income, Q1 FY2024, three months to 2024-03-31−$15.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-05-08, accession 0001708599-25-000053.Report this figure5.2Net income, Q2 FY2024, three months to 2024-06-30$5.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-08-11, accession 0001708599-25-000089.Report this figure1.4Net income, Q3 FY2024, three months to 2024-09-30$1.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-13, accession 0001708599-25-000133.Report this figure(2.7)Net income, Q4 FY2024, three months to 2024-12-31−$2.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-25, accession 0001708599-26-000016. Derived: 12-month figure less the 9-month figure.Report this figure(4.8)Net income, Q1 FY2025, three months to 2025-03-31−$4.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-14, accession 0001708599-26-000035.Report this figure(6.4)Net income, Q2 FY2025, three months to 2025-06-30−$6.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-13, accession 0001708599-26-000047.Report this figure(4.6)Net income, Q3 FY2025, three months to 2025-09-30−$4.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-13, accession 0001708599-25-000133.Report this figure(3.3)Net income, Q4 FY2025, three months to 2025-12-31−$3.3m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-25, accession 0001708599-26-000016. Derived: 12-month figure less the 9-month figure.Report this figure(6.9)Net income, Q1 FY2026, three months to 2026-03-31−$6.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-14, accession 0001708599-26-000035.Report this figure(6.4)Net income, Q2 FY2026, three months to 2026-06-30−$6.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-13, accession 0001708599-26-000047.Report this figure
Diluted EPS$ per share0.23Diluted EPS, Q3 FY2023, three months to 2023-09-30$0.23 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-12, accession 0001708599-24-000026.Report this figurenot reported(5.38)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$5.38 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-08, accession 0001708599-25-000053.Report this figure0.51Diluted EPS, Q2 FY2024, three months to 2024-06-30$0.51 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-11, accession 0001708599-25-000089.Report this figure0.13Diluted EPS, Q3 FY2024, three months to 2024-09-30$0.13 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-13, accession 0001708599-25-000133.Report this figurenot reported(0.49)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.49 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-14, accession 0001708599-26-000035.Report this figure(0.66)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.66 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-13, accession 0001708599-26-000047.Report this figure(0.45)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.45 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-13, accession 0001708599-25-000133.Report this figurenot reported(0.58)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.58 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-14, accession 0001708599-26-000035.Report this figure(0.55)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.55 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-13, accession 0001708599-26-000047.Report this figure
Basic EPS$ per share0.80Basic EPS, Q3 FY2023, three months to 2023-09-30$0.80 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-12, accession 0001708599-24-000026.Report this figurenot reported(5.38)Basic EPS, Q1 FY2024, three months to 2024-03-31−$5.38 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-08, accession 0001708599-25-000053.Report this figure0.61Basic EPS, Q2 FY2024, three months to 2024-06-30$0.61 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-11, accession 0001708599-25-000089.Report this figure0.16Basic EPS, Q3 FY2024, three months to 2024-09-30$0.16 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-13, accession 0001708599-25-000133.Report this figurenot reported(0.49)Basic EPS, Q1 FY2025, three months to 2025-03-31−$0.49 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-14, accession 0001708599-26-000035.Report this figure(0.66)Basic EPS, Q2 FY2025, three months to 2025-06-30−$0.66 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-13, accession 0001708599-26-000047.Report this figure(0.45)Basic EPS, Q3 FY2025, three months to 2025-09-30−$0.45 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-13, accession 0001708599-25-000133.Report this figurenot reported(0.58)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.58 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-14, accession 0001708599-26-000035.Report this figure(0.55)Basic EPS, Q2 FY2026, three months to 2026-06-30−$0.55 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-13, accession 0001708599-26-000047.Report this figure

Balance sheet

Cash and equivalents$23.0m, Q2 FY2026
Long-term debt$11.2m, Q3 FY2024
Shareholders' equity$18.7m, Q2 FY2026
Serina Therapeutics, Inc., balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m0.4Cash and equivalents, Q3 FY2023, at 2023-09-30$397.0k. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2023-11-14, accession 0001493152-23-041126.Report this figure7.6Cash and equivalents, FY2023, at 2023-12-31$7.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-03-24, accession 0001708599-25-000027.Report this figure8.7Cash and equivalents, Q1 FY2024, at 2024-03-31$8.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-05-14, accession 0001493152-24-019248.Report this figure6.1Cash and equivalents, Q2 FY2024, at 2024-06-30$6.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-08-09, accession 0001493152-24-030988.Report this figure3.2Cash and equivalents, Q3 FY2024, at 2024-09-30$3.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-12, accession 0001708599-24-000026.Report this figure3.7Cash and equivalents, FY2024, at 2024-12-31$3.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-03-25, accession 0001708599-26-000016.Report this figure4.3Cash and equivalents, Q1 FY2025, at 2025-03-31$4.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-08, accession 0001708599-25-000053.Report this figure6.0Cash and equivalents, Q2 FY2025, at 2025-06-30$6.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-11, accession 0001708599-25-000089.Report this figure8.6Cash and equivalents, Q3 FY2025, at 2025-09-30$8.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-13, accession 0001708599-25-000133.Report this figure3.1Cash and equivalents, FY2025, at 2025-12-31$3.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-13, accession 0001708599-26-000047.Report this figure24.5Cash and equivalents, Q1 FY2026, at 2026-03-31$24.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-14, accession 0001708599-26-000035.Report this figure23.0Cash and equivalents, Q2 FY2026, at 2026-06-30$23.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-13, accession 0001708599-26-000047.Report this figure
Current assets$m1.1Current assets, Q3 FY2023, at 2023-09-30$1.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-14, accession 0001493152-23-041126.Report this figure7.6Current assets, FY2023, at 2023-12-31$7.6m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-03-24, accession 0001708599-25-000027.Report this figure8.9Current assets, Q1 FY2024, at 2024-03-31$8.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-14, accession 0001493152-24-019248.Report this figure8.9Current assets, Q2 FY2024, at 2024-06-30$8.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-09, accession 0001493152-24-030988.Report this figure5.4Current assets, Q3 FY2024, at 2024-09-30$5.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-12, accession 0001708599-24-000026.Report this figure5.7Current assets, FY2024, at 2024-12-31$5.7m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-03-25, accession 0001708599-26-000016.Report this figure5.8Current assets, Q1 FY2025, at 2025-03-31$5.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-08, accession 0001708599-25-000053.Report this figure8.0Current assets, Q2 FY2025, at 2025-06-30$8.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-11, accession 0001708599-25-000089.Report this figure11.5Current assets, Q3 FY2025, at 2025-09-30$11.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-13, accession 0001708599-25-000133.Report this figure6.1Current assets, FY2025, at 2025-12-31$6.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-13, accession 0001708599-26-000047.Report this figure26.5Current assets, Q1 FY2026, at 2026-03-31$26.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-14, accession 0001708599-26-000035.Report this figure25.0Current assets, Q2 FY2026, at 2026-06-30$25.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-13, accession 0001708599-26-000047.Report this figure
Total assets$m12.2Total assets, Q3 FY2023, at 2023-09-30$12.2m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-14, accession 0001493152-23-041126.Report this figure9.0Total assets, FY2023, at 2023-12-31$9.0m. XBRL concept us-gaap:Assets. 10-K filed 2025-03-24, accession 0001708599-25-000027.Report this figure10.9Total assets, Q1 FY2024, at 2024-03-31$10.9m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-14, accession 0001493152-24-019248.Report this figure10.7Total assets, Q2 FY2024, at 2024-06-30$10.7m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-09, accession 0001493152-24-030988.Report this figure7.4Total assets, Q3 FY2024, at 2024-09-30$7.4m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-12, accession 0001708599-24-000026.Report this figure6.7Total assets, FY2024, at 2024-12-31$6.7m. XBRL concept us-gaap:Assets. 10-K filed 2026-03-25, accession 0001708599-26-000016.Report this figure6.7Total assets, Q1 FY2025, at 2025-03-31$6.7m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-08, accession 0001708599-25-000053.Report this figure8.9Total assets, Q2 FY2025, at 2025-06-30$8.9m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-11, accession 0001708599-25-000089.Report this figure12.4Total assets, Q3 FY2025, at 2025-09-30$12.4m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-13, accession 0001708599-25-000133.Report this figure7.0Total assets, FY2025, at 2025-12-31$7.0m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-13, accession 0001708599-26-000047.Report this figure27.3Total assets, Q1 FY2026, at 2026-03-31$27.3m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-14, accession 0001708599-26-000035.Report this figure25.8Total assets, Q2 FY2026, at 2026-06-30$25.8m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-13, accession 0001708599-26-000047.Report this figure
Current liabilities$m3.2Current liabilities, Q3 FY2023, at 2023-09-30$3.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-14, accession 0001493152-23-041126.Report this figure1.4Current liabilities, FY2023, at 2023-12-31$1.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-03-24, accession 0001708599-25-000027.Report this figure14.1Current liabilities, Q1 FY2024, at 2024-03-31$14.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-14, accession 0001493152-24-019248.Report this figure12.6Current liabilities, Q2 FY2024, at 2024-06-30$12.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-09, accession 0001493152-24-030988.Report this figure13.5Current liabilities, Q3 FY2024, at 2024-09-30$13.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-12, accession 0001708599-24-000026.Report this figure2.4Current liabilities, FY2024, at 2024-12-31$2.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-03-25, accession 0001708599-26-000016.Report this figure2.4Current liabilities, Q1 FY2025, at 2025-03-31$2.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-08, accession 0001708599-25-000053.Report this figure3.6Current liabilities, Q2 FY2025, at 2025-06-30$3.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-11, accession 0001708599-25-000089.Report this figure8.8Current liabilities, Q3 FY2025, at 2025-09-30$8.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-13, accession 0001708599-25-000133.Report this figure3.6Current liabilities, FY2025, at 2025-12-31$3.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-13, accession 0001708599-26-000047.Report this figure6.3Current liabilities, Q1 FY2026, at 2026-03-31$6.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-14, accession 0001708599-26-000035.Report this figure3.8Current liabilities, Q2 FY2026, at 2026-06-30$3.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-13, accession 0001708599-26-000047.Report this figure
Total liabilities$m3.9Total liabilities, Q3 FY2023, at 2023-09-30$3.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-14, accession 0001493152-23-041126.Report this figure4.9Total liabilities, FY2023, at 2023-12-31$4.9m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-03-24, accession 0001708599-25-000027.Report this figure15.2Total liabilities, Q1 FY2024, at 2024-03-31$15.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-14, accession 0001493152-24-019248.Report this figure27.1Total liabilities, Q2 FY2024, at 2024-06-30$27.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-09, accession 0001493152-24-030988.Report this figure21.3Total liabilities, Q3 FY2024, at 2024-09-30$21.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-12, accession 0001708599-24-000026.Report this figure6.2Total liabilities, FY2024, at 2024-12-31$6.2m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-03-25, accession 0001708599-26-000016.Report this figure5.2Total liabilities, Q1 FY2025, at 2025-03-31$5.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-08, accession 0001708599-25-000053.Report this figure7.3Total liabilities, Q2 FY2025, at 2025-06-30$7.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-11, accession 0001708599-25-000089.Report this figure10.8Total liabilities, Q3 FY2025, at 2025-09-30$10.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-13, accession 0001708599-25-000133.Report this figure7.0Total liabilities, FY2025, at 2025-12-31$7.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-13, accession 0001708599-26-000047.Report this figure9.7Total liabilities, Q1 FY2026, at 2026-03-31$9.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-14, accession 0001708599-26-000035.Report this figure7.1Total liabilities, Q2 FY2026, at 2026-06-30$7.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-13, accession 0001708599-26-000047.Report this figure
Long-term debt$mnot reportednot reportednot reportednot reported11.2Long-term debt, Q3 FY2024, at 2024-09-30$11.2m. XBRL concept us-gaap:LongTermDebt. 10-Q filed 2024-11-12, accession 0001708599-24-000026.Report this figurenot reportednot reportednot reportednot reportednot reportednot reportednot reported
Shareholders' equity$m(27.5)Shareholders' equity, Q3 FY2023, at 2023-09-30−$27.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2023-11-14, accession 0001493152-23-041126.Report this figure(32.3)Shareholders' equity, FY2023, at 2023-12-31−$32.3m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2025-03-24, accession 0001708599-25-000027.Report this figure(4.3)Shareholders' equity, Q1 FY2024, at 2024-03-31−$4.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-05-14, accession 0001493152-24-019248.Report this figure(16.4)Shareholders' equity, Q2 FY2024, at 2024-06-30−$16.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-08-09, accession 0001493152-24-030988.Report this figure(13.8)Shareholders' equity, Q3 FY2024, at 2024-09-30−$13.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-12, accession 0001708599-24-000026.Report this figure0.6Shareholders' equity, FY2024, at 2024-12-31$641.0k. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-03-25, accession 0001708599-26-000016.Report this figure1.7Shareholders' equity, Q1 FY2025, at 2025-03-31$1.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-05-08, accession 0001708599-25-000053.Report this figure1.8Shareholders' equity, Q2 FY2025, at 2025-06-30$1.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-08-11, accession 0001708599-25-000089.Report this figure1.8Shareholders' equity, Q3 FY2025, at 2025-09-30$1.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-13, accession 0001708599-25-000133.Report this figure(0.0)Shareholders' equity, FY2025, at 2025-12-31−$37.0k. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-03-25, accession 0001708599-26-000016.Report this figure17.6Shareholders' equity, Q1 FY2026, at 2026-03-31$17.6m. XBRL concept us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest. 10-Q filed 2026-08-13, accession 0001708599-26-000047.Report this figure18.7Shareholders' equity, Q2 FY2026, at 2026-06-30$18.7m. XBRL concept us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest. 10-Q filed 2026-08-13, accession 0001708599-26-000047.Report this figure

Cash flow

Operating cash flow−$6.7m, Q2 FY2026
Capital expenditure$28.0k, Q2 FY2026
Serina Therapeutics, Inc., cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$k(1,024)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$1.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-12, accession 0001708599-24-000026. Derived: 9-month figure less the 6-month figure.Report this figure121Operating cash flow, Q4 FY2023, three months to 2023-12-31$121.0k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-24, accession 0001708599-25-000027. Derived: 12-month figure less the 9-month figure.Report this figure(1,577)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$1.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-08, accession 0001708599-25-000053.Report this figure(8,009)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$8.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-11, accession 0001708599-25-000089. Derived: 6-month figure less the 3-month figure.Report this figure(2,962)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$3.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-13, accession 0001708599-25-000133. Derived: 9-month figure less the 6-month figure.Report this figure(4,589)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$4.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-25, accession 0001708599-26-000016. Derived: 12-month figure less the 9-month figure.Report this figure(4,322)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$4.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-14, accession 0001708599-26-000035.Report this figure(3,750)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$3.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-13, accession 0001708599-26-000047. Derived: 6-month figure less the 3-month figure.Report this figure(3,850)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$3.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-13, accession 0001708599-25-000133. Derived: 9-month figure less the 6-month figure.Report this figure(6,033)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$6.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-25, accession 0001708599-26-000016. Derived: 12-month figure less the 9-month figure.Report this figure(4,568)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$4.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-14, accession 0001708599-26-000035.Report this figure(6,684)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$6.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-13, accession 0001708599-26-000047. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$k119Capital expenditure, Q3 FY2023, three months to 2023-09-30$119.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2024-11-12, accession 0001708599-24-000026. Derived: 9-month figure less the 6-month figure.Report this figure70.0Capital expenditure, Q4 FY2023, three months to 2023-12-31$70.0k. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-K filed 2025-03-24, accession 0001708599-25-000027. Derived: 12-month figure less the 9-month figure.Report this figure14.0Capital expenditure, Q1 FY2024, three months to 2024-03-31$14.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-05-08, accession 0001708599-25-000053.Report this figure0.0Capital expenditure, Q2 FY2024, three months to 2024-06-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-08-11, accession 0001708599-25-000089. Derived: 6-month figure less the 3-month figure.Report this figure3.0Capital expenditure, Q3 FY2024, three months to 2024-09-30$3.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-13, accession 0001708599-25-000133. Derived: 9-month figure less the 6-month figure.Report this figure5.0Capital expenditure, Q4 FY2024, three months to 2024-12-31$5.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-25, accession 0001708599-26-000016. Derived: 12-month figure less the 9-month figure.Report this figure0.0Capital expenditure, Q1 FY2025, three months to 2025-03-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-14, accession 0001708599-26-000035.Report this figure46.0Capital expenditure, Q2 FY2025, three months to 2025-06-30$46.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-13, accession 0001708599-26-000047. Derived: 6-month figure less the 3-month figure.Report this figure13.0Capital expenditure, Q3 FY2025, three months to 2025-09-30$13.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-13, accession 0001708599-25-000133. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2025, three months to 2025-12-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-25, accession 0001708599-26-000016. Derived: 12-month figure less the 9-month figure.Report this figure25.0Capital expenditure, Q1 FY2026, three months to 2026-03-31$25.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-14, accession 0001708599-26-000035.Report this figure28.0Capital expenditure, Q2 FY2026, three months to 2026-06-30$28.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-13, accession 0001708599-26-000047. Derived: 6-month figure less the 3-month figure.Report this figure

Shares

Diluted shares (weighted)16.39m, Q2 FY2026
Serina Therapeutics, Inc., shares, quarterly
Line itemUnitQ3 FY20222022-09-30Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares0.0Diluted shares (weighted), Q3 FY2022, three months to 2022-09-3037,946 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-14, accession 0001493152-23-041126.Report this figure8.6Diluted shares (weighted), Q1 FY2023, three months to 2023-03-318,569,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-14, accession 0001493152-24-019248.Report this figure0.0Diluted shares (weighted), Q2 FY2023, three months to 2023-06-307,434 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-09, accession 0001493152-24-030988.Report this figure7.6Diluted shares (weighted), Q3 FY2023, three months to 2023-09-307,584,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-12, accession 0001708599-24-000026.Report this figure2.8Diluted shares (weighted), Q1 FY2024, three months to 2024-03-312,790,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-08, accession 0001708599-25-000053.Report this figure10.2Diluted shares (weighted), Q2 FY2024, three months to 2024-06-3010,157,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-11, accession 0001708599-25-000089.Report this figure10.8Diluted shares (weighted), Q3 FY2024, three months to 2024-09-3010,751,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-13, accession 0001708599-25-000133.Report this figure9.8Diluted shares (weighted), Q1 FY2025, three months to 2025-03-319,756,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-14, accession 0001708599-26-000035.Report this figure10.0Diluted shares (weighted), Q2 FY2025, three months to 2025-06-3010,004,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-13, accession 0001708599-26-000047.Report this figure10.3Diluted shares (weighted), Q3 FY2025, three months to 2025-09-3010,339,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-13, accession 0001708599-25-000133.Report this figure12.0Diluted shares (weighted), Q1 FY2026, three months to 2026-03-3112,047,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-14, accession 0001708599-26-000035.Report this figure16.4Diluted shares (weighted), Q2 FY2026, three months to 2026-06-3016,385,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-13, accession 0001708599-26-000047.Report this figure

Shares outstanding: 25.40mShares outstanding, period not labelled, at 2026-08-1025,400,473 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-13, accession 0001708599-26-000047.Report this figure at Aug 10, 2026, from the cover of the 10-Q filed Aug 13, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:46 ET. Listed shows no prices and gives no investment advice.